

Q2 and Half-Year Report

H1 2024

SoftOx Solutions AS (ticker: SOFTX) is a Medtech and Clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company has developed a non-toxic and highly effective pan-antimicrobial technology targeting bacteria, viruses, and fungi. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

The SoftOx Solutions Group includes the holding company SoftOx Solutions AS, Water Innovation AB, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is based in Oslo, Norway with subsidiaries in Malmö, Sweden, and Clinical Operations in Copenhagen, Denmark.

Highlights for the first half of 2024

The financial restructuring described in the Annual Report 2023 has continued. The company's creditors, including bondholders and key personnel, have agreed to convert their total outstanding amounts, including accrued interest and costs, totaling NOK 76,2 million, to shares in the company. In addition, the company raised NOK 22,3 million in a private placement divided by NOK 14 million in the conversion of supplier debt and NOK 8,3 million in cash. The extraordinary general assembly (EGA) on the 27th of March 2024 approved the conversion of debt and gave the authority to initiate a repair issue of NOK 15 million towards existing shareholders. The Company raised NOK 2,67 in the repair issue.

The restructuring of the Company continues. The last round of financing before the new Board can take over and the Company is planned to be split into SoftOx Skin and Wound Care AS and SoftOx Inhalation Solutions AS was closed on the 30th of August. The total subscribed amount allocated to investors was MNOK 24,75 with 1.237.508.259 new shares, which included a maximum oversubscription of 10 %.

Based on the request from a large group of shareholders, the Board of Directors has called for an Extraordinary General Assembly (EGA) on the 12th of September 2024 to elect three new Board members; Ulrik Spork (Chairman), Christian Vinding Thomsen (Vice Chairman) and Eskil Zapffe (Board Member), while Geir Hermod Almås (Chairman), Olav Jarlsby and Jørgen Berggrav resign and steps out. The Company would like to use the opportunity to express gratefulness to the outgoing board members for their support and leadership of the company in an extremely difficult period.

As earlier announced, the new Board of Directors intends to carry out the spinout plan put in place by the current Board of Directors and thus expects to call for an Extraordinary General Assembly (EGA) for approval of the distribution of the shares in the yet-to-be-established company SoftOx Skin and Wound Care, as an extraordinary dividend to the shareholders, once all necessary matters have been cleared.

Key figures for the SoftOx Solutions Group as of 30.06.2024

Financial figures for the SoftOx Solutions Group are audited (figures in brackets are comparable figures for 2023).

SoftOx Solutions Group	Second quarter		First Half Year		Year	
NOK 1,000	2024	2023	2024	2023	2024	2023
Total operating revenue	3 062	524	4 877	10 197	4 877	6 980
Total operating expenses	8 703	6 265	19 669	18 368	19 669	39 615
Operating result	-5 640	-5 740	-14 792	-8 171	-14 792	-32 635
Profit before tax	-7 637	-5 441	-28 983	-7 853	-28 983	-42 083
Net proceeds from equity issues	0	0	0	0	0	3 080
Net change in cash and cash equivalents	424	80	424	3 330	424	746
Cash and cash equivalents at end of period	8 075	10 235	8 075	10 242	8 075	7 652
Outstanding shares, beginning of the period	10 727 871	10 342 871	10 727 871	10 342 871	10 727 871	10 342 871
Outstanding shares, end of the period	516 769 641	10 727 871	516 769 641	10 727 871	516 769 641	10 727 871
Employees, end of the period	7	7	7	7	7	7

The Q2 2024 pre-tax results ended with a loss of NOK 7,6 million (loss of NOK 5,4 million). Results are characterized by the restructuring program.

Strategy and Business Segments

SoftOx Solutions is dedicated to developing a completely new class of antimicrobials (infection prevention and infection treatment), that are effective against bacterial infections, viruses, and fungi, without inducing antimicrobial resistance. This new type of antimicrobial is developed to work locally and non-systemically on tissue, whether it is intended for treatment in wounds, the oral cavity, or the respiratory tract, and has shown to be non-toxic.

The Company has developed a patented antimicrobial technology platform over the last 12 years with several antimicrobial products in the pipeline. The Company's business idea is to develop applications for antimicrobial technology to prevent and treat complex microbial infections and illnesses, including multiresistant infections.

SoftOx is committed to developing new ways of eradicating infections and fighting antimicrobial resistance. The focus is to deliver projects from the concept development phase to the partnering phase with the necessary preclinical and clinical documentation. SoftOx is a research and development company, which creates value through developing applications for antimicrobial technology. SoftOx is responsible for progressing projects to achieve the proof of concept (PoC) or proof of sales stage where it is suitable to be taken over by partners. SoftOx is seeking strategic partners depending on the project – industrial, financial, institutional – to help bring the projects to the market and meet user needs.



All SoftOx products utilize the same technology, but the concentrations and formulations are tailored for different uses and indications. The technology is based on a combination of naturally occurring simple chemical compounds that harbour broad antimicrobial effects without inducing resistance.

The current business segments are Inhalation/Respiratory (SoftOx Inhalation Solution), Defence Solution (SoftOx Defence Solution), and Wound Care (SoftOx Skin and Wound Care).

SoftOx Inhalation Solution (SIS)

STRATEGY

Inhalation solutions focus on products to combat infections in the lungs and respiratory system. The SoftOx Inhalation Solution (SIS) is tested to be safe in healthy volunteers (phase 1). Preparation for a proof-of-concept trial (phase 2) in Ventilator Associated Pneumonia (VAP) patients is ongoing. Further, the inhalation solution has many possible indications, including typical viral airway infections like influenza and SARS-CoV-2 as well as bacterial pneumonia and even prevention of infection after exposure.

HIGHLIGHTS RESEARCH & PRODUCT DEVELOPMENT

- The University of Copenhagen on behalf of SoftOx has established proof of concept in mouse models for the use of SIS for both treatment and preventive use against viral infections in the respiratory tract. Animal studies of respiratory infections were concluded to be safe and efficacious.

Q2 and HALF YEAR REPORT 2024

- The SoftOx Research Department led by Prof. Thomas Bjarnsholt has shown broad antimicrobial efficacy of SIS in vitro. Also, in animal models reproducible dose-dependent virucidal effects of inhaled SIS have been shown in mouse models of Influenza A. In addition, the team has shown that the administration of SIS can prevent the spread of Sendai/Parainfluenza virus among co-housed mice. This makes SIS a very promising candidate to prevent and treat airway infections. The team continues to investigate the effects of SIS in animal models.
- LOI with the University of Copenhagen regarding the development of SIS.
- Outsourcing product development to CR Competence.

OUTLOOK

- After careful analysis and consideration, it is decided to focus the research and development on proof of concept (phase 2) in Ventilator Associated Pneumonia (VAP). VAP is a common and lethal threat to hospitalized patients on ventilators. The company already has positive indications of efficacy against VAP.
- During 2023 documentation for applying for a phase 2 study was collected. The study is planned to be executed together with **The Intensive Care Platform Trial (INCEPT)**(<https://incept.dk/>) in **Copenhagen** when the necessary financing is in place. Pending funding, a phase 2 trial can start Ultimo 2025/primo 2026.

SoftOx Defense Solution (SDS)

STRATEGY

Defense Solution develops countermeasures against biological threats through the contract with the European Defence Fund (EDF) together with the Norwegian Defence Research Establishment (FFI) and other European partners. The project started in December 2022 and the project will run until November 2026. The activity in SDS is financed by the contract with the European Defence Fund and has not been affected by the financial challenges in SoftOx Solution.

HIGHLIGHTS RESEARCH & PRODUCT DEVELOPMENT

- SoftOx and its partners were granted approximately NOK 97 million from the European Council in 2022 to develop an inhalation solution for the armed forces within the EU and its allies.
- The project started early 2023 based on new and improved plans.
- In December 2023, SoftOx obtained scientific advice from the Danish Medicines Agency to guide our product development (second generation) and trial design for the upcoming phase 1b trial. We received very useful and relevant feedback from the Danish Medicines Agency, that we are implementing in our non-clinical and clinical strategies.
- The Norwegian Defence Research Institute (FFI) has tested the compatibility of our second-generation SIS on several nebulizer devices available on the market, and a lead device for the upcoming phase 1b trial has been selected.
- The second-generation solutions will be further developed under the EDF project as our next-generation solution. The solution has shown promising stability profiles. Further, the testing of the second-generation SIS has shown great efficacy against a variety of relevant respiratory pathogens including severe pathogens/biological weapons such as Bacillus anthracis (anthrax).

OUTLOOK

- The work on developing Medical Countermeasures against biological warfare agents is progressing according to the project plans.
- In vivo testing in relevant rat and mouse models will take place second half of 2024 and is expected to show good efficacy towards an array of infectious agents (viruses and bacteria).

SoftOx Skin and Wound Care

STRATEGY

Wound Care focuses on cleansing and infection prevention in acute wounds and anti-infective treatments in chronic wounds. SoftOx Biofilm Eradicator (SBE-01) Phase 1 first-in-human study investigating the safety, tolerability, and antimicrobial efficacy of single and multiple doses is completed with very promising results. SoftOx Wound Irrigation Solution for acute wounds ("SWIS-02") showed both significant improvements in wound healing and reduction in bacterial burden compared to saline.

HIGHLIGHTS RESEARCH & PRODUCT DEVELOPMENT

- Due to financial challenges the ongoing work with Wound Care products was paused.
- SoftOx Biofilm Eradicator (SBE) and SoftOx Wound Irrigation Solution (SWIS) have both shown promising results.
- A scientific paper regarding the SoftOx Biofilm Eradicator (SBE-01) Phase 1 first-in-human study has been accepted for publication in 'Advances in Wound Care'.
- SoftOx has started the process of reaching out to relevant actors in the market to investigate the possibilities for cooperation.

OUTLOOK

The current Board of Directors of SoftOx Solutions AS assesses the main value driver within the Skin and Wound Care portfolio to be **SoftOx Biofilm Eradicator (SBE)** and has decided to recommend the following action points to the owners:

- Restructure Skin and Wound Care into a separate non-listed company ('NewCo') which will be the sole owner and developer of the current Skin and Wound Care development projects
 - o A pre-requisite for this spin-out is a guaranteed separate fundraising in "NewCo" of minimum NOK 10 million. The board of Directors recommends a Right Issue to existing shareholders.
- When spin-out is funded and executed, the "Newco" intends to:
 - o Employ new top management to lead NewCo, with experience both from product development in Wound Care and development of companies at this stage.
 - o Minimize cost and maximize access to competencies for NewCo by outsourcing product development of SBE to the European Wound Management Association's Innovation Alliance, to secure both clinical and commercial success.
- Perform a phase 2/3 on SBE after securing sufficient funding.

Financial matters

Financial figures for the SoftOx Solutions Group are audited (figures in brackets are comparable figures for 2023).

Profit and loss statement

First half-year of 2024, the company recognized NOK 4,9 million (NOK 10,2 million) as income in connection with funding from the European Defence Fund and Norwegian Research Fund.

In the first half-year of 2024, salary costs were NOK 2,5 million (NOK 5,7 million). Other operating costs in the first half-year 2024 are NOK 14,3 million (*) (NOK 10,5 million). Total operating expenses in the first half of 2024 are NOK 19,7 million (**) (NOK 18,4 million). Net Financial items for the first half-year of 2024 are NOK 14,2 million (NOK 0,3 million).

(*) NOK 4,75 million in lawyers and consultancy fee restructuring, NOK 1,7 million accrued non-accrued costs set aside for precautionary reasons, NOK 2,7 million project costs EDF/Counteract, NOK 5,1 million operating costs including Un invoiced accrued fees to key personnel/board corresponding to monthly cost NOK 0,85 million.

(**) NOK 2,3 million periodized IP costs.

Pre-tax results ended with a loss of NOK 29 million (loss of NOK 7,9 million) for first half-year 2024. Results are characterized by the restructuring program.

Cash flow and consolidated balance sheet

Of the capitalized assets, the company has activated its IP and patent cost worth NOK 11,1 million (NOK 9,2 million). These are capitalized patent costs in the Swedish subsidiary, which are depreciated over 5 years. Deferred tax assets will not be addressed as the tax calculations will be performed at the end of the year on audited figures.

As reported at the end of the previous quarter, the company has a limited cash position, and there is a need to financially strengthen the company and its liquidity in the short and long term.

Legal Matters

The Company has one unsettled legal issue. One former consultant has filed a claim for a bonus of approximately MNOK 3. This claim is rejected by the Company because the conditions for the bonus were considered not fulfilled. The consultant went to court to claim arrest for the assets of the company. On the 17th of July 2024, Ringerike, Asker og Bærum Tingrett refused to issue an arrest and ruled that the consultant must cover the legal costs of SoftOx. The main trial took place on August 26th and 27th of August 2024. The verdict is expected within a couple of weeks.

The Company has settled another issue related to immaterial rights connected to the further development of Next Generation SoftOx by issuing 16 500 000 new shares.

Other than a dispute with a former employee that has been settled, and the two cases mentioned above, the Company is not, nor has it been, during the preceding 12 months involved in any legal, governmental, or arbitration proceedings which may have, or have had in the recent past, significant effects on the Company's and/or the Group's financial position or profitability, and the Company is not aware of any such proceedings which are pending or threatened.

Option/Warrant Programme

According to the General Assembly 28th June 2024 the Company has issued 30.006.250 stand-alone subscription rights/warrants to employees and board members, as outlined at the list below.

KEY PERSONELL & BOARD			Warrants amount	Warrants	Duration	Strike
Hermod Farms	Geir Almås	Key Personell	1.944.000	9.720.000	5 years	0,4
Harstad Experience	Christian Harstad	Key Personell	1.194.750	5.973.750	5 years	0,4
Medical Consulting	Thomas Bjarnsholdt	Key Personell	895.000	4.475.000	5 years	0,4
Bonica	Ingrid Juven	Key Personell	1.080.000	5.400.000	5 years	0,4
Elin Jørgensen		Key Personell	171.875	859.375	5 years	0,4
Henrik Nielsen		Board	171.875	859.375	5 years	0,4
Olav Jarlsby		Board	171.875	859.375	5 years	0,4
Adrian Bignami		Board	171.875	859.375	5 years	0,4
Jørgen Berggrav		Board	200.000	1.000.000	5 years	0,4
Total			6.001.250	30.006.250		

As part of the reorganization of the Company, the Company informed the stock market on the 12th of August 2024 that the employment contracts with former ECOB and former CEO were terminated by issuing a total amount of approximately 68 million shares.

Significant risk factors for the company

- Clinical research studies always involve an inherent risk of being delayed and not delivering results as expected.
- Financial risks mainly consist of currency, credit, and liquidity risk. The company depends on funding it's R&D activities with funds from investors.
- Intellectual property risks. SoftOx works closely with external patent counsels to minimize the risk of patent infringement claims and prepare any patent defence if necessary.

Declaration by the Board

We confirm, to the best of our knowledge, that the unaudited, summarised half-year report 2024 accounts for the period 1st of January to 30th of June 2024 have been prepared following accounting standards for the group and that the information contained in these accounts gives a true and fair view of the group's assets, liabilities, financial position and profits as a whole, and that the half-year report provides a true and fair view of the information specified in Section 5-6, fourth paragraph, of the Norwegian Securities Trading Act.

Oslo, 11th of September 2024

SIGNED

Geir Hermod Almås, Chairman of the Board

SIGNED

Olav Jarlsby, Board Member

SIGNED

Henrik Nielsen, Board Member

SIGNED

Adrian Bignami, Board Member

SIGNED

Jørgen Berggrav, Board Member

Profit and Loss Statement

Profit and loss statement Accounts for Half Year 2024						
SoftOx Solutions Group <i>NOK 1,000</i>	Second quarter		First Half Year		Year	
	2024	2023	2024	2023	2024	2023
Other operating revenues	3 062	524	4 877	10 197	4 877	6 980
Total operating revenues	3 062	524	4 877	10 197	4 877	6 980
Personnel expenses	1 411	1 322	2 463	5 719	2 463	7 795
Other operating expenses	6 153	3 762	14 284	10 458	14 284	24 341
Depreciation	1 138	1 181	2 922	2 191	2 922	7 479
Depreciation, goodwill	0	-	0	0	0	0
Total operating expenses	8 703	6 265	19 669	18 368	19 669	39 615
Operating result	-5 640	- 5 740	-14 792	-8 171	-14 792	-32 635
Net financial items	-1 997	299	-14 191	318	-14 191	-9 449
Profit before tax	-7 637	- 5 441	-28 983	-7 853	-28 983	-42 083
Tax	0	-	0	0	0	2 635
Annual profit/loss	-7 637	- 5 441	-28 983	-7 853	-28 983	-39 449

Balance sheet 30.06.24

Statement of financial position	30.06.2024	30.06.2023	31.12.2023
SoftOx Solutions Group			
<i>NOK 1,000</i>			
Other intangible assets	11 121	9 248	11 301
Deferred tax asset	76 688	74 053	76 688
Goodwill from acquisition of subsidiary	0	0	0
Total intangible assets	87 809	83 301	87 989
Production equipment	17	3 586	647
Total fixed assets	17	3 586	647
Non-current assets	87 826	86 887	88 637
Inventory	0	0	0
Total inventory	0	0	0
Other receivables	945	5 789	949
Total receivables	945	5 789	949
Cash and cash equivalents	8 075	10 242	6 025
Deposits	0		1 627
Current assets	9 020	16 031	8 602
Total assets	96 847	102 918	97 238

Share capital	10 335	215	215
Share premium reserve	22 396	54 328	58 073
Total paid up capital	32 732	54 542	58 287
Other equity	41 839	-21 016	-55 921
Total equity	74 571	33 527	2 366
Other long term debts	0	40 689	45 589
Other non-current liabilities	0	40 689	45 589
Public duties payable	-380	-449	-70
Shareholder loans	0	0	0
Other current liabilities	12 778	11 633	28 410
Accounts payable	9 878	17 519	20 942
Total current liabilities	22 276	28 703	49 283
Total liabilities	22 276	69 392	94 872
Total equity and liabilities	96 847	102 918	97 238

Cash Flow Statement

Cash flow statement	Second quarter		First Half Year		Year	
	2024	2023	2024	2023	2024	2023
SoftOx Solutions Group						
<i>NOK 1,000</i>						
Cash flow from operating activities						
Net result before taxes	-7 637	-5 441	-28 983	-2 411	-28 983	-42 083
Tax paid	0	0	0	0	0	0
Depreciation	1 138	1 181	2 922	1 010	2 922	7 479
Change in current assets	11	672	4	1 329	4	6 841
Change in current liabilities	-42 844	3 809	-27 007	4 125	-27 007	28 521
Conversion of debts	90 214		90 214		90 214	
Net cash flow from operating activities	-49 333	220	37 150	4 053	37 150	757
Cash flow from investment activities						
Investments in non-current assets	-758	-2 726	-2 112	-481	-2 112	-7 609
Net cash flow from investment activities	-758	-2 726	-2 112	-481	-2 112	-7 609
Cash flow from financing activities						
Proceeds from equity issues	10 994	3 080	10 994	0	10 994	3 080
Other financing activities	-46 067	0	-45 589	-376	-45 589	4 524
Translation differences	-23	-494	-19	54	-19	-4
Net cash flow from financing activities	-35 096	2 586	-34 614	-321	-34 614	7 600
Net change in cash and cash equivalents	424	80	424	3 250	424	746
Cash and cash equivalents at beginning of period	7 652	10 159	7 652	6 907	7 652	6 907
Cash and cash equivalents at end of period	8 075	10 242	8 075	10 242	8 075	7 652

Statement of changes in equity (*)

Statement of changes in equity						
SoftOx Solutions Group						
<i>NOK 1,000</i>						
	Second quarter		First Half Year		Year	
	2024	2023	2024	2023	2024	2023
Equity at end of prior period	-18 976	36 382	2 366	38 741	2 366	38 741
Share issues	101 208	3 080	101 208	3 080	101 208	3 080
Loss for the period	-7 637	-5 441	-28 983	-7 853	-28 983	-39 449
Other changes in equity	-24	54	-21	-440	-21	-6
Equity at end of period	74 571	34 075	74 571	33 528	74 571	2 366

(*) First half-year 2023 and 2024 are before tax, 2023 Full year is after tax, 2024 Full year is before tax.

General accounting Principles

The financial statements have been prepared in accordance with the Norwegian Accounting Act and generally accepted accounting principles in small companies in Norway.

Basis for consolidation

The Group's consolidated financial statements comprise SoftOx Solutions AS and companies in which SoftOx Solutions AS has a controlling interest. A controlling interest is normally obtained when the Group owns more than 50% of the shares in the company and can exercise control over the company. Minority interests are included in the Group's equity. Transactions between group companies have been eliminated in the consolidated financial statement. The consolidated financial statement has been prepared in accordance with the same accounting principles for both parent and subsidiary.

The purchase method is applied when accounting for business combinations. Companies which have been bought or sold during the year are included in the consolidated financial statements from the date when control is achieved and until the date when control ceases.

An associate is an entity in which the Group has a significant influence but does not exercise control the management of its finances and operations (normally when the Group owns 20-50% of the company). The consolidated financial statements include the Group's share of the profits/losses from associates, accounted for using the equity method, from the date when a significant influence is achieved and until the date when such influence ceases.

When the Group's share of a loss exceeds the Group's investment in an associate, the amount carried in the Group's balance sheet is reduced to zero and further losses are not recognized unless the Group has an obligation to cover any such loss.

Use of estimates

The management has used estimates and assumptions that have affected assets, liabilities, incomes, expenses and information on potential liabilities in accordance with generally accepted accounting principles in Norway.

Foreign currency translation

Transactions in foreign currency are translated at the rate applicable on the transaction date. Monetary items in a foreign currency are translated into NOK using the exchange rate applicable on the balance sheet date. Non-monetary items that are measured at their historical price expressed in a foreign currency are translated into NOK using the exchange rate applicable on the transaction date. Non-monetary items that are measured at their fair value expressed in a foreign currency are translated at the exchange rate applicable on the balance sheet date. Changes to exchange rates are recognized in the income statement as they occur during the accounting period.

Revenue recognition

Revenues from the sale of goods are recognized in the income statement once delivery has taken place and most of the risk and return has been transferred. Revenues from the sale of services are recognized in the income statement according to the project's level of completion provided the outcome of the transaction can be estimated reliably. Progress is measured as the number of hours spent compared to the total number of hours estimated. When the outcome of the transaction cannot be estimated reliably, only revenues equal to the project costs that have been incurred will be recognized as revenue. The total estimated loss on a contract will be recognized in the income statement during the period when it is identified that a project will generate a loss.

Income tax

The tax expense consists of the tax payable and changes to deferred tax. Deferred tax/tax assets are calculated on all differences between the book value and tax value of assets and liabilities. Deferred tax is calculated as the tax rate of temporary differences and the tax effect of tax losses carried forward. Deferred tax assets are recorded in the balance sheet when it is more likely than not that the tax assets will

Q2 and HALF YEAR REPORT 2024

be utilized. Taxes payable and deferred taxes are yearly recognized directly in equity to the extent that they relate to equity transactions.

Balance sheet classification

Current assets and short-term liabilities consist of receivables and payables due within one year, and items related to the inventory cycle. Other balance sheet items are classified as fixed assets / long term liabilities. Current assets are valued at the lower of cost and fair value. Short-term liabilities are recognized at nominal value. Fixed assets are valued at cost, less depreciation and impairment losses. Long-term liabilities are recognized at nominal value.

Research and development

Development costs are capitalized providing that a future economic benefit associated with development of the intangible asset can be established and costs can be measured reliably. Otherwise, the costs are expensed as incurred. Capitalized development costs are amortized linearly over their useful life. Research costs are expensed as incurred.

Plant and equipment

Plant and equipment are capitalized and depreciated linearly over the estimated useful life. Significant fixed assets which consist of substantial components with dissimilar economic life have been unbundled; depreciation of each component is based on the economic life of the component. Costs for maintenance are expensed as incurred, whereas costs for improving and upgrading property plant and equipment are added to the acquisition cost and depreciated with the related asset. If the carrying value of a non-current asset exceeds the estimated recoverable amount, the asset is written down to the recoverable amount. The recoverable amount is the greater of the net realisable value and value in use. In assessing value in use, the discounted estimated future cash flows from the asset are discounted.

Subsidiaries

Subsidiaries are valued at cost in the company accounts. The investment is valued as the cost of the shares in the subsidiary, less any impairment losses. An impairment loss is recognized if the impairment is not considered temporary, in accordance with generally accepted accounting principles. Impairment losses are reversed if the reason for the impairment loss disappears in a later period.

Inventories

Inventories are recognized at the lowest of cost and net selling price. The net selling price is the estimated selling price in the case of ordinary operations minus the estimated completion, marketing and distribution costs. The cost is arrived at using the FIFO method and includes the costs incurred in acquiring the goods and the costs of bringing the goods to their current state and location.

Accounts receivable and other receivables

Accounts receivable and other current receivables are recorded in the balance sheet at nominal value less provisions for doubtful accounts. Provisions for doubtful accounts are based on an individual assessment of the different receivables. For the remaining receivables, a general provision is estimated based on expected loss.

Pensions

Under the defined contribution scheme the Group does not commit itself to paying specific future benefits but makes annual contributions to the employees' pension savings. The Group's payment to the defined contribution scheme amounts to 7% of salary for Norwegian employees.

Cash flow statement

The cash flow statement is presented using an indirect method. Cash and cash equivalents include cash, bank deposits and other short term, highly liquid investments with maturities of three months or less.

Glossary

CBRN	Chemical, Biological, Radiological and Nuclear
EDF	European Defence Fund
EN	European Norm
EU	European Union
FDA	U.S. Food and Drug Administration
IP	Intellectual property
Kemi	Swedish Chemicals Agency
MRSA	Methicillin-resistant Staphylococcus aureus
OTA	Other Transaction Agreement
R&D	Research and Development
SBE	SoftOx Biofilm Eradicator (SoftOx Infection Remover)
SDS	SoftOx Defense Solutions AS
Shares	SoftOx Solutions issued and outstanding shares, unless the context indicates otherwise, including the Offer Shares offered in the Offering.
SIS	SoftOx Inhalation Solution
SWIS	SoftOx Wound Irrigation Solution

Contact us

SoftOx Solutions AS

Martin Linges vei 25

1364 Fornebu

Norway

<https://soft-ox.com/>